Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.93 USD | +4.94% | +3.21% | +71.61% |
09/05 | Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02/05 | Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+71.61% | 148.75Cr | |
+3.91% | 11TCr | |
+10.87% | 11TCr | |
+0.06% | 2.23TCr | |
-13.14% | 2.21TCr | |
-7.61% | 1.87TCr | |
-38.36% | 1.76TCr | |
-10.66% | 1.69TCr | |
+3.75% | 1.38TCr | |
+36.70% | 1.25TCr |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Wells Fargo Lifts Aeglea BioTherapeutics to Overweight From Equalweight, Price Target to $2 From $1.50